Proposed Merger Shows That When It Comes to Gene Editing, You Ain’t Seen Nothing Yet

Writing for SeedWorld, Rory Riggs discusses the proposed Cibus–Calyxt merger and what it signals for the next phase of precision gene editing in agriculture — combined patent portfolios, production capacity, and the path to commercial-scale gene-edited traits.

The piece follows the same production-discipline argument Riggs makes throughout his work on Pharma & Life Sciences: that gene editing in agriculture is entering the same maturity curve pharmaceutical development went through decades earlier.

Read the article at SeedWorld →

Scroll to Top